Novartis' cholesterol drug pelacarsen fails to reduce heart attack and stroke risk in late-stage study, impacting investor ...

Biocon has signed a significant 10-year contract to supply pertuzumab, a breast cancer drug, in Brazil, emphasizing its ...

Novo Nordisk announces the termination of two heart drug trials for ziltivekimab, casting doubt on its diversification ...

New Zealand's health authorities have granted approval for the use of MDMA in treating severe PTSD, making it only the second country to do so. This move follows Australia's recent decision and ...

HRV Pharma, based in Hyderabad, is set to invest ₹150 crore to enhance its peptide manufacturing capabilities and develop high-potency oncology APIs, aiming to meet industry demands for specialized ...

Novo Nordisk reports a significant reduction in obesity rates among children aged 6 to under 12 treated with semaglutide in a recent clinical trial, highlighting potential for systemic obesity ...

Novartis India has announced the acquisition of Pfizer's hypertension drug Minipress for ₹1250 crore, aiming to enhance its product portfolio while Pfizer navigates sales declines in the wake of COVID ...

RPG Life Sciences plans to invest Rs 500 crore over the next year to enhance its manufacturing and Active Pharmaceutical Ingredients (API) capabilities, targeting significant growth in revenue and ...

Piyush Goyal calls for regulatory alignment with developed countries to boost investment and innovation in India's pharmaceutical industry.

The European Medicines Agency reviews injectable iron medicines due to concerns about low phosphate levels and potential bone disorders. The assessment follows reports of serious adverse effects, ...

Medical experts caution consumers about the use of experimental injectable peptides for weight loss and anti-aging, emphasizing the importance of safety and regulation, especially amidst rising ...

Novartis' experimental heart drug pelacarsen missed key goals in a late-stage trial, leading to a significant drop in shares for both Novartis and partner Ionis Pharmaceuticals. This setback raises ...